FIELD: biotechnology.
SUBSTANCE: presented is the use of a B-cell inhibitor which does not lead to depletion for reducing immunogenicity in a subject receiving or having received a gene therapy. B-cell inhibitor is a bispecific antibody to CD32B and CD79B.
EFFECT: invention can find further application in therapy.
15 cl, 10 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
| MOLECULES WITH CD45 AND CD79 SPECIFICITY | 2015 |
|
RU2747980C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| COVALENT DIABODIES AND USE THEREOF | 2009 |
|
RU2744176C2 |
| MOLECULES WITH SPECIFICITY WITH RESPECT TO CD79 AND CD22 | 2015 |
|
RU2743590C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
